A Resource from the American College of Preventive Medicine
There is debate over the clinical utility of the Metabolic Syndrome (MetS), in particular, whether the combination of metabolic risk factors that defines it actually adds value to traditional cardiovascular risk assessment. Debate also revolves around its pathogenesis because it is not completely understood. The risk of uncertainty is a diminishing perception of value. But there are some undeniable certainties about the MetS. It is inseparable from the obesity epidemic. As obesity increases, so does the MetS. Two out of three adults are overweight or obese, and half of them have the MetS. And it is being seen at younger and younger ages. The MetS is vitally important to recognize and address in primary care because it identifies those whose excess weight poses the greatest health risk. Having the syndrome makes Type 2 diabetes nearly inevitable without intervention, and it doubles the risk for cardiovascular disease. There is no debate over the need to take the MetS seriously. It is a lifestyle disease, caused by a lifestyle of too much food and too little activity. It provides a red flag for clinicians and patients that lifestyle changes are needed now. If it is ignored, it will progress toward diabetes and heart disease. The statistics are alarming, but the consequences of inaction are much more alarming.
The Metabolic Syndrome Time Tool developed by the American College of Preventive Medicine is an innovative educational tool designed to assist the physician in a brief consult on the Metabolic Syndrome. It will increase awareness, provide education, and offer the guidance of the best evidence and guidelines in the delivery of an effective intervention. The tool includes an executive summary of the evidence and a practical approach to delivering the needed services to patients in the context of a clinical visit. It is complemented by a robust clinical reference document delineating the epidemiology, the clinical evidence, recommendations by various professional and government entities, and additional resources.
This educational activity is intended for primary care physicians.
After completing this program, physician participants should be able to:
Diagnose and explain the Metabolic Syndrome in the clinical setting
Describe the etiology of fat cell expansion and development of insulin resistance
Discuss the health risks that are caused and/or exacerbated by the syndrome
Explain why lifestyle modification is the first line approach to treatment, and the changes needed to reverse the syndrome
Understand the basics of the Chronic Care Model and how it can be used to change the organization of the practice
TERM OF APPROVAL
May 2009 through June 2011. Original release date: May 2009
These materials have been reviewed by the members of the American College of Preventive Medicine to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias.
David M. Ferriss, MD, MPH
Pamela L. Morris, MD, FACC, FACP, FACPM
Medical University of South Carolina
James A. Underberg, MD, MS, FACPM, FACP
New York University Medical School
New York, NY
In the interest of providing an educational experience free of commercial bias, and as the accredited provider of CME for this activity, the American College of Preventive Medicine was responsible for decisions regarding educational content and allocation of funds. All individuals involved in the planning, development, and delivery of educational activities are required to sign a conflict of interest statement in which they disclose any relevant financial interests or other affiliations with industry or other associations which may have direct and substantial interest in the subject matter of the CME activity. Such disclosure allows program participants to better evaluate the objectivity of the information presented in the program.
David M. Ferriss, MD, MPH, is an employee of CIGNA Healthcare.
Pamela L. Morris, MD serves on speakers bureaus for Abbott Laboratories, Astra Zeneca and Takeda.
James A. Underberg, MD, MS serves on speakers bureaus for Abbott Laboratories, Merck/Schering-Plough Pharmaceuticals, Novartis Pharmaceuticals, Daiichi Sankyo, Pfizer, Astra Zeneca, GlaxoSmithKline and as a consultant for Liposcience.
Larry Mattson, Medical Writer, has disclosed no financial relationships.
These pages may be viewed using standard Internet browser applications (e.g. Internet Explorer). They may also be downloaded as PDFs and read using standard PDF reader applications (e.g. Adobe Acrobat Reader).
The American College of Preventive Medicine collects personal information from participants in this online activity for purposes of assigning CME credit only. We will not share or sell your contact information, and your answers to quizzes and feedback forms will be kept confidential.
This material is copyright of the American College of Preventive Medicine.
If you have questions regarding this CME activity, please contact Haydee Barno at email@example.com.
Metabolic Syndrome Patient Guide
CLICK FOR METABOLIC SYNDROME TIME TOOL